From the Kilimanjaro Summit

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

After months of training, hundreds of hours spent in a high-altitude sleep tent, and almost a week spent ascending the mountain, our climbing group was destined to have only 12 minutes at Mt. Kilimanjaro’s summit. However, that was enough to pay tribute to the 200,000 heroes who have participated in more than a half-century of SWOG cancer clinical trials.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Charles D. Blanke
Chair of SWOG; Professor of medicine at the Knight Cancer Institute at the Oregon Health and Science University

YOU MAY BE INTERESTED IN

For decades, we have faced a central challenge in colorectal cancer screening. One in three eligible Americans—over 50 million people—remain unscreened despite established methods like colonoscopy or stool-based tests existing for decades. This gap persists even though early detection saves lives, and even as colorectal cancer is now the number one cancer killer for Americans under 50.
Charles D. Blanke
Chair of SWOG; Professor of medicine at the Knight Cancer Institute at the Oregon Health and Science University

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login